Quarterly Updates5 Feb 2026, 02:28 pm
Anthem Biosciences Reports 24.8% PAT Margins for 9MFY26 with Revenues at $15,134 Mn
AI Summary
Anthem Biosciences Limited, an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO), announced unaudited results for the third quarter and period ended December 31, 2025. The company reported consolidated revenue from operations at $15,134 Mn for 9MFY26, with EBITDA at $26,712 Mn (41.5% EBITDA margins) and PAT at $74,020 Mn (24.8% PAT margins). The quarterly consolidated revenue from operations stood at $4,232 Mn with EBITDA at $1,907 Mn (41.8% EBITDA margins) and PAT at $928 Mn (20.3% PAT margins).
Key Highlights
- Consolidated revenue from operations for 9MFY26 stood at $15,134 Mn
- EBITDA for 9MFY26 was $26,712 Mn with 41.5% EBITDA margins
- PAT for 9MFY26 was $74,020 Mn with 24.8% PAT margins
- Quarterly consolidated revenue from operations was $4,232 Mn
- Q3FY26 EBITDA stood at $1,907 Mn with 41.8% EBITDA margins
- Q3FY26 PAT was $928 Mn with 20.3% PAT margins